search

Propanc Biopharma, Inc. Common Stock (PPCB)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
Oct 30, 2026

Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients

Propanc Biopharma, Inc. (Nasdaq: PPCB) is making significant strides in its bioanalytical and immunogenicity assay development for its planned Phase 1b, First-In-Human study of PPC-001. This study will involve up to 50 advanced cancer patients with solid tumors. Key progress includes encouraging stability results for PPC-001 in human blood, successful application of mass spectrometry for proenzyme measurement, and advancements in anti-drug antibody assay development, all crucial steps towards clinical readiness.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish